Skip to main content
. 2017 Feb 13;12(2):e0171827. doi: 10.1371/journal.pone.0171827

Fig 2.

Fig 2

A. Triptolide prodrug Minnelide induces tumor regression in mouse models for gastric cancer. Treatment of mice bearing subcutaneous xenograft tumors derived from MKN45 gastric adenocarcinoma cells with Minnelide (0.21 mg/kg) as well as Minnelide (0.42mg/kg) led to a significant reduction in tumor burden compared to control (saline treated) mice. Tumor volumes were assessed twice weekly. Mice were followed for 21 days. B. Ex-vivo volumes of the MKN45 derived subcutaneous tumors. C. Ex vivo pictures of MKN45 cell derived tumors from mice treated with Minnelide were significantly smaller than the controls. D. Treatment of mice bearing subcutaneous xenograft tumors derived from MKN28 gastric adenocarcinoma cells with Minnelide (0.21 mg/kg) as well as Minnelide (0.42mg/kg) led to a reduction in tumor burden compared to control (saline treated) mice. Tumor volumes were assessed twice weekly. Mice were followed for 42 days. E Ex-vivo volumes of the MKN28 derived subcutaneous tumors. F. Ex vivo pictures of MKN28 cell derived tumors from mice treated with Minnelide were smaller than the controls. G. TUNEL staining of MKN45 as well as MKN28 tumors from mice treated with Minnelide showed significantly higher apoptotic cells than the saline treated mice as evidenced by greater numbers of TUNEL positive cells in the Minnelide treated groups. * indicates p value < 0.05 when compared to untreated.